The wealthy entrepreneur: I want to support millions of employees!.

Chapter 1037 The Truth Behind Romi Bio's Acquisition! The Middleman Profits the Difference!
You can tell that Song Mingliang is quite energetic; he speaks with a strong voice.

"By the way, boss, I recently contacted two overseas medical companies that are interested in our RomiBio research direction..."

"Not bad!" Su Yang said with a little performance, "Which two are they?"

"Ais from Switzerland, and Hurui Times from Germany!" Perhaps fearing that Su Yang might not know these two companies, Song Mingliang explained briefly, "Both of these companies are quite powerful in Europe, and they are willing to send people to our country for inspection!"

Upon hearing the name of the Swiss company, Su Yang narrowed his eyes.

Song Mingliang contacted overseas pharmaceutical companies to inspect RomiBio, which is no problem and proves his ability. As a general manager, he should share the company's burdens!
Domestic innovative drug companies almost all go global by relying on the model of "independent research and development + overseas licensing".

On average, it takes 10 years and more than $10 billion for a new drug to go from research and development to market, and the failure rate is extremely high. That's why companies need to keep raising funds... because no single capital firm can afford such a risk!
By collaborating with overseas companies, it's like having capital invest in you; everyone can share resources and share risks and costs.

Even domestic innovative drug giants lack overseas sales channels, doctor networks, and so on. If an overseas pharmaceutical giant is interested in RomiBio's unfinished products, they can use milestone payments to obtain overseas authorization for RomiBio's products in advance.

Domestic innovative drug companies are doing quite well. They excel at early discovery and rapid clinical development, while multinational pharmaceutical companies have stronger basic scientific research capabilities, world-class technology platforms, and mature distribution channels.

They also have extensive experience and resources in operating international multi-center clinical trials, which can accelerate clinical research and simultaneously apply for market approval from multiple regulatory agencies such as the US FDA and the European EMA, greatly shortening the time to global drug launch.

Innovative pharmaceutical companies can obtain valuable cash flow from these international pharmaceutical giants to support research and development. At the same time, by cooperating with these international giants, innovative pharmaceutical companies can gain strong brand endorsement and enhanced reputation!

The cooperation between the two parties can achieve a result greater than the sum of its parts (1+1>2).

The anthelmintic developed by Chuanrong Veterinary Medicine has shown good results in clinical trials, but it has yet to be launched on the market.

This is still overseas. If the company applies overseas, it could be delayed for several years!
Song Mingliang wanted to monetize Romi Bio's research results ahead of time. If he could successfully monetize them ahead of time, Romi Bio would no longer need to rely on Su Yang for continuous financial support!
"Very good, you did a great job!" Su Yang said with a smile. "Remember to let me know the results after they've finished their inspection!"

"Good boss!"

After hanging up with Song Mingliang, Su Yang started thinking about the Swiss Acer Pharmaceuticals matter again.

Before acquiring RomiBio, he learned through business analysis that if he did not acquire RomiBio but only supported its research and development through financing, RomiBio's research and development would achieve a certain breakthrough in the near future.

In April of this year, Aisi will acquire RomiBio's unfinished bispecific antibody drug for a milestone payment of one billion US dollars, and obtain the global (excluding China) rights to develop, manufacture and commercialize the drug.

Milestone payments in the innovative drug industry are not one-time payments.

It refers to a model where overseas partners pay domestic pharmaceutical companies after reaching certain pre-agreed key milestones.

Milestone payments are typically combined with down payments and sales commissions to form a complete installment payment plan. The core of this plan is "pay-for-achievement," which links payments to key progress in R&D, registration, and commercialization.

It should be noted that there is uncertainty regarding the eventual fulfillment of milestone payments.

If a drug fails in clinical development or fails to obtain regulatory approval, the corresponding milestone payments will not be triggered.

Therefore, this is also a payment method that involves R&D risks.

What caught Su Yang's attention most was that after acquiring the bispecific antibody drug LM8012 for a billion-dollar milestone payment, Aisi Medical acquired RomiBio for another billion dollars around September of this year...

Why did it acquire RomiBio?
Su Yang had been keeping an eye on this matter. Unfortunately, the business simulation only covered a year, making it difficult for Su Yang to predict events beyond that timeframe.
Su Yang thought for a moment, began to consider various possibilities, and repeatedly conducted business simulations of the company.

[First Month: RomiBio's Biologics' Bispecific Anti-tumor Drug (LM8012) Achieves Breakthrough Progress...]

Su Yang raised an eyebrow slightly. The research and development progress was ahead of schedule, probably due to the research and development buff!
[Second month: The drug enters the clinical trial phase...]

[In the third month: Global pharmaceutical giants Merck and GSK experienced multiple failures in their bispecific antibody clinical trials, while LM8012, with its superior clinical data, rose to second place globally… Swiss company Acer and German company Hurricane Medical are both very interested in the enormous therapeutic potential of the bispecific antibody drug (LM8012). Acer Medical has offered a milestone payment of one billion US dollars in collaboration, hoping to obtain subsequent research results and overseas licensing!]

After thinking about it for a moment, Su Yang decided to accept it!
Only by accepting this can we deduce the reasons behind Aisi's acquisition of Romi Bio!

[Fourth Month: Aisi Medical paid an initial payment of $60 million to acquire subsequent R&D results and overseas licensing for its bispecific anti-tumor drug (LM8012)!]

[Fifth month: ...]

[Sixth Month: Aisi Medical made an acquisition offer for RomiBio at a valuation of one billion US dollars. Song Mingliang, Su Yaohui, and other shareholders of the company were very excited. You...]

This is also the main reason why Su Yang acquired Romi Bio.

Because once you buy it, you can indeed sell it at a high price very quickly!

Putting aside whether it's for sale or not, at least the company can be monetized and has value!

Su Yang thought about it for a moment and decided to agree, but he had to be involved.

[Seventh Month: You actively fought for control of the company, and the R&D team led by Su Yaohui also supported you. Ultimately, Aisi Medical made concessions, acquiring 80% of Romi Bio's shares for $800 million... You, along with Su Yaohui, gained control of the company through an A/B share structure!]

When Su Yang's entrepreneur level was upgraded to level six last time, he didn't necessarily need to own more than 50% of the shares. As long as he had control, the company could be considered his!
[Eighth month: ...]

[Ninth Month: Acquisition Agreement Signed...]

[Tenth Month: ...Ais Medical paid an initial payment of US$30 million to acquire 80% of RomiBio's shares, and the bispecific anti-tumor drug (LM8012) was officially renamed the bispecific anti-tumor drug (AS735).]

[Eleventh Month: ...]

Su Yang leisurely picked up his teacup and took a sip, hoping to figure out what Aisi Medical was up to. He hoped to gain something from this experience.

He tried last month, but was still stuck in the twelfth month!

[Month 12: ...Bristol-Myers Squibb (BMS) plans to invest $114 billion to jointly develop a bispecific antibody drug for AS735 with Swiss medical technology company Acer, expanding into the global market. RomiBio's R&D capabilities have garnered global attention...]

"Grass!"

Even the usually civilized Su Yang couldn't help but swear!

(End of this chapter)